News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|December 19, 2024

Key Differences in Onset, Progression, Diagnosis, and Treatment of Pediatric Vitiligo

Author(s)Lawrence Eichenfield, MD

Key Takeaways

Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Collaborating With Communities to Manage Pediatric Vitiligo

1 KOL is featured in this series.

EP. 2 Anticipating Advances for Pediatric Vitiligo

1 KOL is featured in this series.

EP. 3 Telehealth and Research Strides for Young Patients

1 KOL is featured in this series.

EP. 4 Managing Expectations and Holistically Treating Patients With Vitiligo

1 KOL is featured in this series.

EP. 5 Vitiligo Repigmentation Challenges and Evaluating Treatment Success

1 KOL is featured in this series.

EP. 6 Clinical Presentation

1 KOL is featured in this series.

EP. 7 Promising and Emerging Therapies in the Vitiligo Landscape

1 KOL is featured in this series.

EP. 8 The JAK Revolution in Vitiligo

1 KOL is featured in this series.

EP. 9 Balancing Safety and Efficacy With Key Data

1 KOL is featured in this series.

EP. 10 Vitiligo Treatment Patterns and Pearls for Adults Versus Pediatric Patients

1 KOL is featured in this series.

EP. 11 Tailoring Treatments and Counseling Patients With Pediatric Vitiligo

1 KOL is featured in this series.

EP. 12 Safety, Efficacy, and Treatment Adherence in Young Patients With Vitiligo

EP. 13 Treatment Insights and Evolving Care Options in Vitiligo

EP. 13 Treatment Insights and Evolving Care Options in Vitiligo

1 KOL is featured in this series.

EP. 14 Key Differences in Onset, Progression, Diagnosis, and Treatment of Pediatric Vitiligo

1 KOL is featured in this series.

EP. 15 Addressing Psychological and Social Impacts of Pediatric Vitiligo

1 KOL is featured in this series.

EP. 16 Promoting Open and Positive Dialogue With Families of Patients With Pediatric Vitiligo

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Reviewing Type 2 Inflammation Through a Different Lens

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

© 2025 MJH Life Sciences^®

All rights reserved.